retatrutide positive effects Lindsay Maggio, MD, MPH | 📣 News you need to know — is almost here, and the data is remarkable. Eli Lilly just released Phase 3 results for retatrutide, Retatrutide UK 2026: Phase 3

Nonetheless, investigators from the Canadian Network for Observational Drug Effect Studies (CNODES) reported contradictory results

At the highest dose (36 mg/day), orforglipron led to an average weight loss of 11.2% over 72 weeks

2 Majority of patients were treated with standard of care 1,2,n,o Summary of medication at baseline (N=3533) 1,2 Select CV and CKD baseline characteristics (N=3533) 1,2 n At baseline patients in FLOW were receiving standard-of-care background therapy, including a maximum tolerated label dose of a RAAS-blocking agent including an ACE inhibitor or an ARB, unless such treatment was contraindicated or not tolerated

Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses

Inflammation Acne, irritation, and skin trauma can trigger post-inflammatory pigmentation